PortfoliosLab logoPortfoliosLab logo
DFTX vs. LRCX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

DFTX vs. LRCX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, DFTX achieves a 170.20% return, which is significantly higher than LRCX's 117.34% return.


DFTX

1D
-1.34%
1M
60.80%
YTD
170.20%
6M
158.06%
1Y
444.47%
3Y*
122.15%
5Y*
10Y*

LRCX

1D
-9.33%
1M
21.69%
YTD
117.34%
6M
112.40%
1Y
307.58%
3Y*
84.36%
5Y*
43.85%
10Y*
48.36%
*Multi-year figures are annualized to reflect compound growth (CAGR)

DFTX vs. LRCX - Yearly Performance Comparison


2026 (YTD)2025202420232022
DFTX
Definium Therapeutics, Inc
170.20%92.39%90.16%66.36%-78.74%
LRCX
Lam Research Corporation
117.34%139.16%-6.84%88.63%2.02%

Correlation

The correlation between DFTX and LRCX is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Jul 11, 2022

0.22

Fundamentals

Market Cap

DFTX:

$3.94B

LRCX:

$468.91B

EPS

DFTX:

-$2.57

LRCX:

$5.29

PB Ratio

DFTX:

14.12

LRCX:

44.30

Total Revenue (TTM)

DFTX:

$0.00

LRCX:

$21.68B

Gross Profit (TTM)

DFTX:

$0.00

LRCX:

$10.84B

EBITDA (TTM)

DFTX:

-$206.36M

LRCX:

$6.10B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

DFTX vs. LRCX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DFTX
DFTX Risk / Return Rank: 9999
Overall Rank
DFTX Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
DFTX Sortino Ratio Rank: 9999
Sortino Ratio Rank
DFTX Omega Ratio Rank: 9797
Omega Ratio Rank
DFTX Calmar Ratio Rank: 9999
Calmar Ratio Rank
DFTX Martin Ratio Rank: 9999
Martin Ratio Rank

LRCX
LRCX Risk / Return Rank: 9898
Overall Rank
LRCX Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
LRCX Sortino Ratio Rank: 9797
Sortino Ratio Rank
LRCX Omega Ratio Rank: 9696
Omega Ratio Rank
LRCX Calmar Ratio Rank: 9999
Calmar Ratio Rank
LRCX Martin Ratio Rank: 9999
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DFTX vs. LRCX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


DFTXLRCXDifference
Sharpe ratioReturn per unit of total volatility

+0.01

Sortino ratioReturn per unit of downside risk

+1.02

Omega ratioGain probability vs. loss probability

1.66

1.61

+0.05

Calmar ratioReturn relative to maximum drawdown

18.08

15.49

+2.59

Martin ratioReturn relative to average drawdown

56.98

51.63

+5.36

DFTX vs. LRCX - Sharpe Ratio Comparison

The current DFTX Sharpe Ratio is 5.72, which is comparable to the LRCX Sharpe Ratio of 5.71. The chart below compares the historical Sharpe Ratios of DFTX and LRCX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

DFTX vs. LRCX - Drawdown Comparison

The maximum DFTX drawdown since its inception was -86.01%, roughly equal to the maximum LRCX drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for DFTX and LRCX.


Loading charts...

Drawdown Indicators


DFTXLRCXDifference

Max Drawdown

Largest peak-to-trough decline

-86.01%

-87.90%

+1.89%

Max Drawdown (1Y)

Largest decline over 1 year

-24.79%

-20.01%

-4.78%

Max Drawdown (3Y)

Largest decline over 3 years

-58.38%

-47.10%

-11.28%

Max Drawdown (5Y)

Largest decline over 5 years

-56.39%

Max Drawdown (10Y)

Largest decline over 10 years

-56.39%

Current Drawdown

Current decline from peak

-1.34%

-9.33%

+7.99%

Average Drawdown

Average peak-to-trough decline

-50.92%

-28.15%

-22.77%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.85%

5.99%

+1.86%

Volatility

DFTX vs. LRCX - Volatility Comparison

Definium Therapeutics, Inc (DFTX) has a higher volatility of 41.87% compared to Lam Research Corporation (LRCX) at 24.10%. This indicates that DFTX's price experiences larger fluctuations and is considered to be riskier than LRCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DFTXLRCXDifference

Volatility (1M)

Calculated over the trailing 1-month period

41.87%

24.10%

+17.77%

Volatility (6M)

Calculated over the trailing 6-month period

55.58%

44.78%

+10.80%

Volatility (1Y)

Calculated over the trailing 1-year period

78.68%

54.30%

+24.38%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

87.37%

46.97%

+40.40%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

87.37%

45.11%

+42.26%

Dividends

DFTX vs. LRCX - Dividend Comparison

DFTX has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.28%.


PositionTTM20252024202320222021202020192018201720162015
DFTX
Definium Therapeutics, Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LRCX
Lam Research Corporation
0.28%0.57%1.19%0.95%1.53%0.78%1.04%1.54%2.79%1.01%1.28%1.36%

Financials

DFTX vs. LRCX - Financials Comparison

This section allows you to compare key financial metrics between Definium Therapeutics, Inc and Lam Research Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B6.00B202220232024202520260
5.84B
(DFTX) Total Revenue
(LRCX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


DFTX and LRCX have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

DFTX has higher volatility (41.87%) compared to LRCX (24.10%). In terms of maximum drawdown, DFTX dropped -86.01% vs LRCX's -87.90%.

DFTX currently has the higher Sharpe Ratio (5.72 vs 5.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for DFTX and LRCX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer